How can one trust that a drug manufacturer’s product is safe for public consumption (in this case injection) when money is being blatantly passed between the drug company (in this case Merck manufacturer of the Gardasil HPV vaccine) and a well-respected source for medical information? Where are the ethics?
Leslie Carol Botha: Only the Facts Ma’am – When one reads the politics and the science behind the marketing and the safety and efficacy of the Gardasil HPV vaccine approved for use for women ages 27 to 45 in Canada, one begins to wonder – is this vaccination really going to benefit this age group or is it just another way for Merck make a profit on an unwitting demographic.
The Center for the Biology of Chronic Disease (CBCD) has learned that Merck recently funded a study conducted by Dr. Chun Chao from Kaiser Permanente. USA Today reported: “Study: No link between HPV vaccine and autoimmune disorders” on January 28, 2012. In the opening paragraph, the story says that “The human papillomavirus (HPV) vaccine Gardasil does not trigger autoimmune disorders.”
Should the reader believe the report? Is it possible that the researchers, who conducted the study, are biased?
Vac Truth By Jeffry John Aufderheide | January 9th, 2012 Sometimes gems are difficult to come by. However, when we find them, just clean them up a bit and we can appreciate their ‘real value’. The little treasure I discovered was a document located on Merck Pharmaceutical’s website. It disclosed how much Merck paid doctors Continue Reading …
Merck could increase the size of the dividend payment it makes to shareholders every quarter following its $41.1 billion purchase of rival Schering-Plough, although the company will not commit to an increase now.
Chief Financial Officer Peter Kellogg told analysts and investors Thursday that Merck “will be generating a lot of cash” and that the company does see the need to “ultimately make sure shareholders benefit from that.” He also said, “It’s too early to declare how we will do that.”
Merck published fake journal The following is an excerpted article that was originally published in TheScientist.com. To read the full article, with citations, click on the hyper link below. The Inconvenient Woman thought it was very important to illustrate the prevasive corporate culture of deception that has taken over the once respected Pharma Giant, Merck. Continue Reading …
Merck to buy Schering-Plough in $41 billion deal Reported by David Jolly Publ With the purchase, Merck is expanding its franchise in cardiovascular, respiratory and oncology drugs and shoring up its research pipeline, in particular with a Schering-Plough product called TRA, a promising drug designed to prevent blood clotting. In addition, Merck will benefit from the Continue Reading …
The forth quarter earning reports, the report card for publicly held companies, held no good news for Merck or its stockholders. Merck released its not overly optimistic guidance for 2009 that forecasted earnings and revenue below that expected by Wall Street analysts. It is never a good to disappoint ‘the street.’ Merck named lower sales of its Vytorin and Zetia cholesterol pills, sold as part of a joint venture with Schering-Plough as one reason for declining profit.